Asia Pacific Lung Cancer Diagnostics Market
Market Size in USD Billion
CAGR :
% 
 Forecast Period |
2024 –2030 |
 Market Size (Base Year) |
|
 Market Size (Forecast Year) |
|
 CAGR |
% |
| Major Markets Players |
Asia-Pacific Lung Cancer Diagnostics Market, By Product Type (Instruments, Consumables & Accessories), Test Type (Biomarkers Test, Imaging Test, Biopsy, Blood Test, and Others), Cancer Type (Non-Small Cell Lung Cancer, Small Cell Lung Cancer), End User (Hospital, Associated Labs, Independent Diagnostic Laboratories, Diagnostic Imaging Centers, Cancer Research Institutes, and Others), Distribution Channel (Direct Tender, Retail Sales) - Industry Trends and Forecast to 2030.
Asia-Pacific Lung Cancer Diagnostics Market Analysis and Insights
The Asia-Pacific lung cancer diagnostics market is expected to grow in the forecast year due to the rise in market players and the availability of advanced services. Along with this, manufacturers are engaged in R&D activity for launching novel services in the market. Increasing lung cancer diagnosis and development research is further projected to boost market growth. However, difficulties in lung cancer screening techniques might hamper the growth of the Asia-Pacific lung cancer diagnostics market in the forecast period.
Increasing healthcare expenditure on cancer diagnosis and treatment is expected to give opportunities to the market to enhance the treatment. However, the high cost of testing and strict regulations and standards for the approval and commercialization of cancer diagnostic products may challenge market growth.
The Asia-Pacific lung cancer diagnostics market is supportive and aims to reduce the progression of the disease. Data Bridge Market Research analyses that the Asia-Pacific lung cancer diagnostics market will grow at a CAGR of 16.0% during the forecast period of 2023 to 2030.
|
Report Metric |
Details |
|
Forecast Period |
2023 to 2030 |
|
Base Year |
2022 |
|
Historic Years |
2021 (Customizable to 2020 - 2015) |
|
Quantitative Units |
Revenue in USD Million, Pricing in USD |
|
Segments Covered |
Product Type (Instruments, Consumables & Accessories), Test Type (Biomarkers Test, Imaging Test, Biopsy, Blood Test, and Others), Cancer Type (Non-Small Cell Lung Cancer, Small Cell Lung Cancer), End User (Hospital, Associated Labs, Independent Diagnostic Laboratories, Diagnostic Imaging Centers, Cancer Research Institutes, and Others), Distribution Channel (Direct Tender, Retail Sales) |
|
Countries Covered |
China, Japan, India, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam, New Zealand, Taiwan and Rest of Asia-Pacific |
|
Market Players Covered |
F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott, Quest Diagnostics Incorporated, Biodesix, Amoy Diagnostics Co., Ltd., Bio-Rad Laboratories, Inc., Biocartis, Boditech Med Inc., Danaher, Vela Diagnostics, DiaSorin S.p.A., Exact Sciences UK, Ltd. (a subsidiary of Exact Science Corporation), 20/20 Gene Systems, Guardant Health, Inc., Inivata Ltd., LalPathLabs.com, LungLife AI, Inc., MedGenome, Myriad Genetics, Inc., NeoGenomics Laboratories, NanoString, Nanoentek, Oncocyte Corporation, PerkinElmer Inc., PlexBio, QIAGEN, Siemens Healthcare GmbH, and Veracyte, Inc. among others |
Market Definition
Cancer begins in the lungs and most often occurs in people who smoke. Two major types of lung cancer are non-small cell lung cancer and small cell lung cancer. Causes of lung cancer include smoking, second-hand smoke, exposure to certain toxins, and family history.
Symptoms include a cough (often with blood), chest pain, wheezing, and weight loss. These symptoms often don't appear until the cancer is advanced. Treatments vary but may include surgery, chemotherapy, radiation therapy, targeted drug therapy, and immunotherapy.
Asia-Pacific Lung Cancer Diagnostics Market Dynamics
This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail below:
- Increasing early diagnosis of lungs cancer
Machine learning could revolutionize early cancer diagnosis, which trains computers to see patterns in complex data. Tools include assessments of common health data, medical imaging, biopsy samples, and blood tests to help in early diagnosis and risk stratification. In many tumor types, the likelihood of undergoing successful therapy increases with an early cancer diagnosis. One important strategy is to assess patients at risk who do not exhibit symptoms and respond quickly and appropriately to those who do.
The likelihood of successfully treating cancer is considerably increased by early identification. The two elements of early cancer detection are screening and early diagnosis (or downstaging). While screening consists of evaluating healthy individuals to find those who have cancer before any symptoms occur, early diagnosis focuses on identifying symptomatic patients as early as feasible.
- Detection of early-stage cancers often limited by high false positives and poor sensitivity
The creation of non-invasive tests that can quickly and reliably identify whether and where in the body a person has early-stage cancer is one of the most promising areas of cancer prevention research. And not just one cancer but a variety of cancers. On this front, significant advancements have been made in recent years. Several multi-cancer early detection (MCED) tests are currently under development, and they are designed to screen for multiple cancer types in otherwise healthy individuals simultaneously. However, detecting early-stage cancer is a challenge as it comes with many barriers, such as high false positives or poor sensitivity. Many cases of poor diagnostics sensitivity lead to a patient's life at risk. The high false positives are also one of the causes of cancer advancing to late stages or advanced stages.
Thus, the detection of early-stage cancers is often limited by high false positives, and sometimes poor sensitivity may act as a major restraining factor for the growth of the Asia-Pacific lung cancer diagnostics market.
- Rise in healthcare expenditure for cancer diagnosis and treatment
Across the globe, research and development activities are escalating owing to the public health expenditure with economic performances. Whereas the healthcare industry ranks second among all industries when it comes to the amount spent on healthcare. Rising healthcare expenditure can result in better provision of research and development opportunities. It is anticipated to increase the demand for lung cancer diagnostics. Increasing the healthcare expenditure for cancer treatment also helps the patient take hassle-free advanced diagnostics and treatment for fast recovery. The spending on healthcare is made up of the combination of out-of-pocket payments (people paying for their care), government expenditure, and sources. It also includes health insurance and activities by non-governmental organizations. This increasing healthcare expenditure for cancer treatment is an opportunity to grow the market's demand.
- Lack of skilled and certified professionals
The requirement of skilled and certified professionals is a big restraint for cancer diagnostics. The demand for cancer diagnostic is increased due to increasing cases of cancer disease in the globe, but the fewer number of skilled professionals present in the diagnostic center is hampering the growth of the market.
The instruments, methods, and procedures of cancer diagnosis have been advanced, but there are certain gaps in standardization, equalization, and knowledge. Technicians face technical training gaps related to problems and adapt advanced methods safely to perform procedures efficiently. In cancer diagnostics, skilled professionals are highly needed for method development, validation, operation, and troubleshooting activities.
A cancer diagnosis is a dynamic component in today's complex time, providing patients with essential information for diagnosing, preventing, treating, and managing their cancer disease. The requirement for trained staff is a big issue for the Asia-Pacific lung cancer diagnostics market. Due to the lack of skilled and certified professionals, end users cannot install advanced products for a cancer diagnosis; this may challenge the growth of the Asia-Pacific lung cancer diagnostics market.
Post-COVID-19 Impact on Asia-Pacific Lung Cancer Diagnostics Market
The high burden of COVID-19 on healthcare systems around the world has raised concerns among medical oncologists about the impact of COVID-19 on lung cancer diagnosis and treatment. We investigated the impact of COVID-19 on lung cancer diagnosis and treatment before and after the COVID-19 era in this retrospective cohort study. During the pandemic, new lung cancer diagnoses decreased by 34.7% with slightly more advanced stages of the disease, and there was a significant increase in radiosurgery as the first definitive treatment and a decrease in systemic treatment and surgery compared to the pre-COVID-19 era. Compared to pre-COVID-19 times, there was no significant delay in starting chemotherapy and radiation treatment during the pandemic.
During the pandemic, however, we observed a delay in lung cancer surgery. COVID-19 appears to have significantly impacted lung cancer patients' diagnoses and treatment patterns at our lung cancer center. Many oncologists are concerned that the number of newly diagnosed lung cancer patients will rise in the coming year. This research is still ongoing, and more information will be gathered and analyzed to understand better the overall impact of the COVID-19 pandemic on our lung cancer patient population.
Recent Developments
- In October 2022, Quest Diagnostics announced a new chapter of the partnership with Decode Health. This partnership has aided the business in decreasing the time and expense involved in creating fresh diagnostic tests and finding new medication targets for various cancers and increased the company's Asia-Pacific presence
- In August 2022, F. Hoffmann-La Roche Ltd. announced the launch of a Digital LightCycler System, a next-generation digital PCR system that helps clinical researchers better understand the nature of a patient's cancer, genetic disease, or infection. This system is designed for laboratories performing highly sensitive and precise DNA and RNA analysis in oncology and infectious diseases
Asia-Pacific Lung Cancer Diagnostics Market Scope
The Asia-Pacific lung cancer diagnostics market is categorized into five notable segments based on product type, test type, cancer type, end user, and distribution channel. The growth amongst these segments will help you analyse meager growth segments in the industries and provide the users with a valuable market overview and market insights to make strategic decisions to identify core market applications.
Product Type
- Instruments
- Consumables & Accessories
On the basis of product type, the Asia-Pacific lung cancer diagnostics market is segmented into instruments, consumables & accessories.
Test Type
- Biomarkers Tests
- Imaging Test
- Biopsy
- Blood Test
- Others
On the basis of test type, the Asia-Pacific lung cancer diagnostics market is segmented into imaging test, biomarkers test, biopsy, blood test, and others.
Cancer Type
- Non-Small Cell Lung Cancer
- Small Cell Lung Cancer
On the basis of cancer type, the Asia-Pacific lung cancer diagnostics market is segmented into non-small cell lung cancer and small cell lung cancer.
End User
- Hospital
- Associated Labs
- Independent Diagnostic Laboratories
- Diagnostic Imaging Centers
- Cancer Research Institutes
- Others
On the basis of end user, the Asia-Pacific lung cancer diagnostics market is segmented into hospital, associated labs, independent diagnostics laboratories, diagnostic imaging centers, cancer research institutes, and others.
Distribution Channel
- Direct Tender
- Retail Sales
On the basis of distribution channel, the Asia-Pacific lung cancer diagnostics market is segmented into direct tender and retail sales.
Asia-Pacific Lung Cancer Diagnostics Market Regional Analysis/Insights
The Asia-Pacific lung cancer diagnostics market is analyzed, and market size insights and trends are provided by country, product type, test type, cancer type, end user, and distribution channel, as referenced above.
Some countries covered in the Asia-Pacific lung cancer diagnostics market are China, Japan, India, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam, and Rest of Asia-Pacific.
China is expected to dominate the Asia-Pacific lung cancer diagnostics market due to the rise in chronic diseases with the growing integration of healthcare data with portable devices.
The country section of the report also provides individual market-impacting factors and changes in market regulation that impact the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of Asia-Pacific brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Asia-Pacific Lung Cancer Diagnostics Market Share Analysis
The Asia-Pacific lung cancer diagnostics market competitive landscape provides details by the competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, Asia-Pacific presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points provided are only related to the companies focus on the Asia-Pacific lung cancer diagnostics market.
Some players in the Asia-Pacific lung cancer diagnostics market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott, Quest Diagnostics Incorporated, Biodesix, Amoy Diagnostics Co., Ltd., Bio-Rad Laboratories, Inc., Biocartis, Boditech Med Inc., Danaher, Vela Diagnostics, DiaSorin S.p.A., Exact Sciences UK, Ltd. (a subsidiary of Exact Science Corporation), 20/20 Gene Systems, Guardant Health, Inc., Inivata Ltd., LalPathLabs.com, LungLife AI, Inc., MedGenome, Myriad Genetics, Inc., NeoGenomics Laboratories, NanoString, Nanoentek, Oncocyte Corporation, PerkinElmer Inc., PlexBio, QIAGEN, Siemens Healthcare GmbH, and Veracyte, Inc. among others.
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF ASIA PACIFIC LUNG CANCER DIAGNOSTICS MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 PRODUCT TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET TESTING TYPE COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PORTER’S FIVE FORCES
4.2 PESTEL ANALYSIS
4.3 INDUSTRY INSIGHTS
5 EPIDERMIOLOGY
6 REGULATIONS
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 UNMET NEED FOR NON-INVASIVE, ACCURATE, AND RELIABLE DIAGNOSTIC TESTS FOR EARLIER CANCER DETECTION
7.1.2 INCREASING EARLY DIAGNOSIS OF LUNGS CANCER
7.1.3 INCREASING CASES OF LUNG CANCER
7.1.4 RISE IN PRODUCT APPROVALS
7.2 RESTRAINTS
7.2.1 POOR & LATE DIAGNOSIS OF LUNG CANCER
7.2.2 HIGH FALSE-POSITIVES AND POOR SENSITIVITY
7.3 OPPORTUNITIES
7.3.1 RISE IN HEALTHCARE EXPENDITURE FOR CANCER DIAGNOSIS AND TREATMENT
7.3.2 GOVERNMENT INITIATIVES TOWARD CANCER DIAGNOSTICS
7.3.3 RISING AWARENESS OF LUNG CANCER
7.4 CHALLENGES
7.4.1 STRINGENT REGULATORY FRAMEWORK FOR THE APPROVAL AND COMMERCIALIZATION OF CANCER DIAGNOSTIC PRODUCTS
7.4.2 INCREASED COST, SAFETY, AND CONVENIENCE ISSUES
7.4.3 LACK OF SKILLED AND CERTIFIED PROFESSIONALS
8 ASIA PACIFIC LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE
8.1 OVERVIEW
8.2 INSTRUMENTS
8.2.1 IMAGING INSTRUMENTS
8.2.1.1 CT SYSTEMS
8.2.1.2 ULTRASOUND SYSTEMS
8.2.1.3 MRI SYSTEMS
8.2.1.4 OTHERS
8.2.2 BIOPSY INSTRUMENTS
8.2.2.1 NEEDLE BIOPSY
8.2.2.2 ENDOSCOPIC BIOPSY
8.2.2.3 CORE BIOPSY
8.2.2.4 OTHERS
8.2.3 PATHOLOGY-BASED INSTRUMENTS
8.2.3.1 SLIDE STAINING SYSTEMS
8.2.3.2 TISSUE PROCESSING SYSTEMS
8.2.3.3 CELL PROCESSORS
8.2.3.4 PCR INSTRUMENTS
8.2.3.5 OTHERS PATHOLOGY-BASED INSTRUMENTS
8.3 CONSUMABLES AND ACCESSORIES
8.3.1 KITS
8.3.1.1 DNA POLYMERASE KITS
8.3.1.2 NUCLEIC ACID ISOLATION KITS
8.3.1.3 PCR KITS
8.3.1.4 OTHERS
8.3.2 REAGENTS
8.3.2.1 ASSAYS
8.3.2.2 BUFFERS
8.3.2.3 PRIMERS
8.3.2.4 OTHERS
8.3.3 PROBES
8.3.4 OTHER CONSUMABLES
9 ASIA PACIFIC LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE
9.1 OVERVIEW
9.2 IMAGING TEST
9.2.1 COMPUTED TOMOGRAPHY (CT) SCAN
9.2.2 POSITRON EMISSION TOMOGRAPHY (PET) SCAN
9.2.3 CHEST X-RAY
9.2.4 BONE SCAN
9.2.5 MRI
9.2.6 OTHERS
9.3 BIOMARKERS TEST
9.3.1 EGFR MUTATION TEST
9.3.2 KRAS MUTATION TEST
9.3.3 ALK TEST
9.3.4 HER2 TEST
9.3.5 OTHERS
9.4 BIOPSY
9.4.1 NEEDLE BIOPSY
9.4.2 BRONCHOSCOPY BIOPSY
9.4.3 CORE BIOPSY
9.4.4 OTHERS
9.5 BLOOD TEST
9.5.1 COMPLETE BLOOD COUNT (CBC)
9.5.2 BLOOD CHEMISTRY TESTS
9.5.3 OTHERS
9.6 OTHERS
10 ASIA PACIFIC LUNG CANCER DIAGNOSTICS MARKET, BY CANCER TYPE
10.1 OVERVIEW
10.2 NON-SMALL CELL LUNG CANCER
10.3 SMALL CELL LUNG CANCER
11 ASIA PACIFIC LUNG CANCER DIAGNOSTICS MARKET, BY END USER
11.1 OVERVIEW
11.2 HOSPITAL
11.3 ASSOCIATED LABS
11.4 INDEPENDENT DIAGNOSTIC LABORATORIES
11.5 DIAGNOSTIC IMAGING CENTERS
11.6 CANCER RESEARCH INSTITUTES
11.7 OTHERS
12 ASIA PACIFIC LUNG CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL
12.1 OVERVIEW
12.2 DIRECT TENDER
12.3 RETAIL SALES
13 ASIA PACIFIC LUNG CANCER DIAGNOSTICS MARKET, BY REGION
13.1 ASIA-PACIFIC
13.1.1 CHINA
13.1.2 JAPAN
13.1.3 SOUTH KOREA
13.1.4 AUSTRALIA
13.1.5 INDIA
13.1.6 SINGAPORE
13.1.7 INDONESIA
13.1.8 PHILIPPINES
13.1.9 VIETNAM
13.1.10 MALAYSIA
13.1.11 THAILAND
13.1.12 NEW ZEALAND
13.1.13 TAIWAN
13.1.14 REST OF ASIA-PACIFIC
14 ASIA PACIFIC LUNG CANCER DIAGNOSTICS MARKET, COMPANY LANDSCAPE
14.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC
15 SWOT ANALYSIS
16 COMPANY PROFILE
16.1 F. HOFFMANN-LA ROCHE LTD. (2022)
16.1.1 COMPANY SNAPSHOT
16.1.2 REVENUE ANALYSIS
16.1.3 COMPANY SHARE ANALYSIS
16.1.4 PRODUCT PORTFOLIO
16.1.5 RECENT DEVELOPMENTS
16.2 THERMO FISHER SCIENTIFIC INC. (2022)
16.2.1 COMPANY SNAPSHOT
16.2.2 REVENUE ANALYSIS
16.2.3 COMPANY SHARE ANALYSIS
16.2.4 PRODUCT PORTFOLIO
16.2.5 RECENT DEVELOPMENTS
16.3 ABBOTT (2022)
16.3.1 COMPANY SNAPSHOT
16.3.2 REVENUE ANALYSIS
16.3.3 COMPANY SHARE ANALYSIS
16.3.4 PRODUCT PORTFOLIO
16.3.5 RECENT DEVELOPMENTS
16.4 QUEST DIAGNOSTICS INCORPORATED (2022)
16.4.1 COMPANY SNAPSHOT
16.4.2 REVENUE ANALYSIS
16.4.3 COMPANY SHARE ANALYSIS
16.4.4 PRODUCT PORTFOLIO
16.4.5 RECENT DEVELOPMENTS
16.5 BIODESIX (2022)
16.5.1 COMPANY PROFILE
16.5.2 REVENUE ANALYSIS
16.5.3 COMPANY SHARE ANALYSIS
16.5.4 PRODUCT PORTFOLIO
16.5.5 RECENT DEVELOPMENTS
16.6 AMOY DIAGNOSTICS CO., LTD. (2022)
16.6.1 COMPANY SNAPSHOT
16.6.2 PRODUCT PORTFOLIO
16.6.3 RECENT DEVELOPMENTS
16.7 BIO-RAD LABORATORIES, INC. (2022)
16.7.1 COMPANY SNAPSHOT
16.7.2 REVENUE ANALYSIS
16.7.3 PRODUCT PORTFOLIO
16.7.4 RECENT DEVELOPMENTS
16.8 BIOCARTIS (2022)
16.8.1 COMPANY SNAPSHOT
16.8.2 REVENUE ANALYSIS
16.8.3 PRODUCT PORTFOLIO
16.8.4 RECENT DEVELOPMENTS
16.9 BODITECH MED INC.
16.9.1 COMPANY PROFILE
16.9.2 PRODUCT PORTFOLIO
16.9.3 RECENT DEVELOPMENTS
16.1 DANAHER (2022)
16.10.1 COMPANY SNAPSHOT
16.10.2 REVENUE ANALYSIS
16.10.3 PRODUCT PORTFOLIO
16.10.4 RECENT DEVELOPMENTS
16.11 DIASORIN S.P.A. (2022)
16.11.1 COMPANY SNAPSHOT
16.11.2 REVENUE ANALYSIS
16.11.3 PRODUCT PORTFOLIO
16.11.4 RECENT DEVELOPMENTS
16.12 EXACT SCIENCES UK, LTD. (SUBSIDIARY OF EXACT SCIENCE CORPORATION) (2022)
16.12.1 COMPANY SNAPSHOT
16.12.2 REVENUE ANALYSIS
16.12.3 PRODUCT PORTFOLIO
16.12.4 RECENT DEVELOPMENTS
16.13 20/20 GENE SYSTEMS
16.13.1 COMPANY PROFILE
16.13.2 PRODUCT PORTFOLIO
16.13.3 RECENT DEVELOPMENTS
16.14 GUARDANT HEALTH INC.
16.14.1 COMPANY PROFILE
16.14.2 PRODUCT PORTFOLIO
16.14.3 RECENT DEVELOPMENTS
16.15 INIVATA LTD.
16.15.1 COMPANY PROFILE
16.15.2 PRODUCT PORTFOLIO
16.15.3 RECENT DEVELOPMENTS
16.16 LALPATHLABS.COM (2022)
16.16.1 COMPANY SNAPSHOT
16.16.2 REVENUE ANALYSIS
16.16.3 PRODUCT PORTFOLIO
16.16.4 RECENT DEVELOPMENTS
16.17 LUNGLIFE AI, INC. (2022)
16.17.1 COMPANY SNAPSHOT
16.17.2 PRODUCT PORTFOLIO
16.17.3 RECENT DEVELOPMENTS
16.18 MEDGENOME
16.18.1 COMPANY SNAPSHOT
16.18.2 PRODUCT PORTFOLIO
16.18.3 RECENT DEVELOPMENTS
16.19 MYRIAD GENETICS, INC.
16.19.1 COMPANY SNAPSHOT
16.19.2 PRODUCT PORTFOLIO
16.19.3 RECENT DEVELOPMENTS
16.2 NEOGENOMICS LABORATORIES (2022)
16.20.1 COMPANY SNAPSHOT
16.20.2 REVENUE ANALYSIS
16.20.3 PRODUCT PORTFOLIO
16.20.4 RECENT DEVELOPMENTS
16.21 NANOSTRING (2022)
16.21.1 COMPANY SNAPSHOT
16.21.2 REVENUE ANALYSIS
16.21.3 PRODUCT PORTFOLIO
16.21.4 RECENT DEVELOPMENTS
16.22 NANOENTEK
16.22.1 COMPANY PROFILE
16.22.2 PRODUCT PORTFOLIO
16.22.3 RECENT DEVELOPMENTS
16.23 ONCOCYTE CORPORATION
16.23.1 COMPANY PROFILE
16.23.2 SERVICE PORTFOLIO
16.23.3 RECENT DEVELOPMENTS
16.24 PERKINELMER INC
16.24.1 COMPANY PROFILE
16.24.2 REVENUE ANALYSIS
16.24.3 PRODUCT PORTFOLIO
16.24.4 RECENT DEVELOPMENTS
16.25 PLEXBIO
16.25.1 COMPANY SNAPSHOT
16.25.2 PRODUCT PORTFOLIO
16.25.3 RECENT DEVELOPMENTS
16.26 QIAGEN
16.26.1 COMPANY SNAPSHOT
16.26.2 REVENUE ANALYSIS
16.26.3 PRODUCT PORTFOLIO
16.26.4 RECENT DEVELOPMENTS
16.27 SIEMENS HEALTHCARE GMBH
16.27.1 COMPANY SNAPSHOT
16.27.2 REVENUE ANALYSIS
16.27.3 PRODUCT PORTFOLIO
16.27.4 RECENT DEVELOPMENTS
16.28 VERACYTE, INC. (2022)
16.28.1 COMPANY SNAPSHOT
16.28.2 REVENUE ANALYSIS
16.28.3 PRODUCT PORTFOLIO
16.28.4 RECENT DEVELOPMENTS
16.29 VELA DIAGNOSTICS
16.29.1 COMPANY PROFILE
16.29.2 PRODUCT PORTFOLIO
16.29.3 RECENT DEVELOPMENTS
17 QUESTIONNAIRE
18 RELATED REPORTS
List of Table
TABLE 1 DIFFERENT TYPES OF CANCER SCREENING TESTS FOR DIFFERENT TYPES OF CANCERS
TABLE 2 LUNG CANCER RATES
TABLE 3 APPROVED DIAGNOSTICS OF LUNGS CANCER
TABLE 4 ASIA PACIFIC LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 5 ASIA PACIFIC INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 6 ASIA PACIFIC IMAGING INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 7 ASIA PACIFIC BIOPSY INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 8 ASIA PACIFIC PATHOLOGY-BASED INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 9 ASIA PACIFIC CONSUMABLES & ACCESSORIES IN LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 10 ASIA PACIFIC CONSUMABLES AND ACCESSORIES IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 11 ASIA PACIFIC KITS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 12 ASIA PACIFIC REAGENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 13 ASIA PACIFIC LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 14 ASIA PACIFIC IMAGING TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 15 ASIA PACIFIC IMAGING TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 16 ASIA PACIFIC BIOMARKERS TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 17 ASIA PACIFIC BIOMARKERS TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 18 ASIA PACIFIC BIOPSY IN LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 19 ASIA PACIFIC BIOPSY IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 20 ASIA PACIFIC BLOOD TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 21 ASIA PACIFIC BLOOD TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 22 ASIA PACIFIC OTHERS IN LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 23 ASIA PACIFIC LUNG CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 24 ASIA PACIFIC NON-SMALL CELL LUNG CANCER IN LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 25 ASIA PACIFIC SMALL CELL LUNG CANCER IN LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 26 ASIA PACIFIC LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 27 ASIA PACIFIC HOSPITAL IN LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 28 ASIA PACIFIC ASSOCIATED LABS IN LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 29 ASIA PACIFIC INDEPENDENT DIAGNOSTIC LABORATORIES IN LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 30 ASIA PACIFIC DIAGNOSTIC IMAGING CENTERS IN LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 31 ASIA PACIFIC CANCER RESEARCH INSTITUTES IN LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 32 ASIA PACIFIC OTHERS IN LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 33 ASIA PACIFIC LUNG CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 34 ASIA PACIFIC DIRECT TENDER IN LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 35 ASIA PACIFIC RETAIL SALES IN LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 36 ASIA-PACIFIC LUNG CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 37 ASIA-PACIFIC LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 38 ASIA-PACIFIC INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 39 ASIA-PACIFIC PATHOLOGY-BASED INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 40 ASIA-PACIFIC IMAGING INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 41 ASIA-PACIFIC BIOPSY INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 42 ASIA-PACIFIC CONSUMABLES AND ACCESSORIES IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 43 ASIA-PACIFIC KITS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 44 ASIA-PACIFIC REAGENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 45 ASIA-PACIFIC LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 46 ASIA-PACIFIC BIOMARKERS TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 47 ASIA-PACIFIC IMAGING TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 48 ASIA-PACIFIC BIOPSY IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 49 ASIA-PACIFIC BLOOD TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 50 ASIA-PACIFIC LUNG CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 51 ASIA-PACIFIC LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 52 ASIA-PACIFIC LUNG CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 53 CHINA LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 54 CHINA INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 55 CHINA PATHOLOGY-BASED INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 56 CHINA IMAGING INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 57 CHINA BIOPSY INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 58 CHINA CONSUMABLES AND ACCESSORIES IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 59 CHINA KITS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 60 CHINA REAGENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 61 CHINA LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 62 CHINA BIOMARKERS TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 63 CHINA IMAGING TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 64 CHINA BIOPSY IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 65 CHINA BLOOD TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 66 CHINA LUNG CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 67 CHINA LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 68 CHINA LUNG CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 69 JAPAN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 70 JAPAN INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 71 JAPAN PATHOLOGY-BASED INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 72 JAPAN IMAGING INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 73 JAPAN BIOPSY INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 74 JAPAN CONSUMABLES AND ACCESSORIES IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 75 JAPAN KITS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 76 JAPAN REAGENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 77 JAPAN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 78 JAPAN BIOMARKERS TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 79 JAPAN IMAGING TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 80 JAPAN BIOPSY IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 81 JAPAN BLOOD TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 82 JAPAN LUNG CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 83 JAPAN LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 84 JAPAN LUNG CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 85 SOUTH KOREA LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 86 SOUTH KOREA INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 87 SOUTH KOREA PATHOLOGY-BASED INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 88 SOUTH KOREA IMAGING INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 89 SOUTH KOREA BIOPSY INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 90 SOUTH KOREA CONSUMABLES AND ACCESSORIES IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 91 SOUTH KOREA KITS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 92 SOUTH KOREA REAGENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 93 SOUTH KOREA LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 94 SOUTH KOREA BIOMARKERS TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 95 SOUTH KOREA IMAGING TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 96 SOUTH KOREA BIOPSY IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 97 SOUTH KOREA BLOOD TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 98 SOUTH KOREA LUNG CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 99 SOUTH KOREA LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 100 SOUTH KOREA LUNG CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 101 AUSTRALIA LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 102 AUSTRALIA INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 103 AUSTRALIA PATHOLOGY-BASED INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 104 AUSTRALIA IMAGING INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 105 AUSTRALIA BIOPSY INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 106 AUSTRALIA CONSUMABLES AND ACCESSORIES IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 107 AUSTRALIA KITS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 108 AUSTRALIA REAGENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 109 AUSTRALIA LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 110 AUSTRALIA BIOMARKERS TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 111 AUSTRALIA IMAGING TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 112 AUSTRALIA BIOPSY IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 113 AUSTRALIA BLOOD TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 114 AUSTRALIA LUNG CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 115 AUSTRALIA LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 116 AUSTRALIA LUNG CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 117 INDIA LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 118 INDIA INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 119 INDIA PATHOLOGY-BASED INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 120 INDIA IMAGING INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 121 INDIA BIOPSY INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 122 INDIA CONSUMABLES AND ACCESSORIES IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 123 INDIA KITS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 124 INDIA REAGENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 125 INDIA LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 126 INDIA BIOMARKERS TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 127 INDIA IMAGING TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 128 INDIA BIOPSY IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 129 INDIA BLOOD TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 130 INDIA LUNG CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 131 INDIA LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 132 INDIA LUNG CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 133 SINGAPORE LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 134 SINGAPORE INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 135 SINGAPORE PATHOLOGY-BASED INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 136 SINGAPORE IMAGING INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 137 SINGAPORE BIOPSY INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 138 SINGAPORE CONSUMABLES AND ACCESSORIES IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 139 SINGAPORE KITS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 140 SINGAPORE REAGENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 141 SINGAPORE LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 142 SINGAPORE BIOMARKERS TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 143 SINGAPORE IMAGING TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 144 SINGAPORE BIOPSY IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 145 SINGAPORE BLOOD TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 146 SINGAPORE LUNG CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 147 SINGAPORE LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 148 SINGAPORE LUNG CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 149 INDONESIA LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 150 INDONESIA INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 151 INDONESIA PATHOLOGY-BASED INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 152 INDONESIA IMAGING INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 153 INDONESIA BIOPSY INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 154 INDONESIA CONSUMABLES AND ACCESSORIES IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 155 INDONESIA KITS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 156 INDONESIA REAGENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 157 INDONESIA LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 158 INDONESIA BIOMARKERS TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 159 INDONESIA IMAGING TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 160 INDONESIA BIOPSY IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 161 INDONESIA BLOOD TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 162 INDONESIA LUNG CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 163 INDONESIA LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 164 INDONESIA LUNG CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 165 PHILIPPINES LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 166 PHILIPPINES INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 167 PHILIPPINES PATHOLOGY-BASED INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 168 PHILIPPINES IMAGING INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 169 PHILIPPINES BIOPSY INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 170 PHILIPPINES CONSUMABLES AND ACCESSORIES IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 171 PHILIPPINES KITS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 172 PHILIPPINES REAGENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 173 PHILIPPINES LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 174 PHILIPPINES BIOMARKERS TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 175 PHILIPPINES IMAGING TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 176 PHILIPPINES BIOPSY IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 177 PHILIPPINES BLOOD TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 178 PHILIPPINES LUNG CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 179 PHILIPPINES LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 180 PHILIPPINES LUNG CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 181 VIETNAM LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 182 VIETNAM INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 183 VIETNAM PATHOLOGY-BASED INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 184 VIETNAM IMAGING INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 185 VIETNAM BIOPSY INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 186 VIETNAM CONSUMABLES AND ACCESSORIES IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 187 VIETNAM KITS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 188 VIETNAM REAGENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 189 VIETNAM LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 190 VIETNAM BIOMARKERS TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 191 VIETNAM IMAGING TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 192 VIETNAM BIOPSY IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 193 VIETNAM BLOOD TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 194 VIETNAM LUNG CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 195 VIETNAM LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 196 VIETNAM LUNG CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 197 MALAYSIA LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 198 MALAYSIA INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 199 MALAYSIA PATHOLOGY-BASED INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 200 MALAYSIA IMAGING INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 201 MALAYSIA BIOPSY INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 202 MALAYSIA CONSUMABLES AND ACCESSORIES IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 203 MALAYSIA KITS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 204 MALAYSIA REAGENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 205 MALAYSIA LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 206 MALAYSIA BIOMARKERS TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 207 MALAYSIA IMAGING TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 208 MALAYSIA BIOPSY IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 209 MALAYSIA BLOOD TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 210 MALAYSIA LUNG CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 211 MALAYSIA LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 212 MALAYSIA LUNG CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 213 THAILAND LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 214 THAILAND INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 215 THAILAND PATHOLOGY-BASED INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 216 THAILAND IMAGING INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 217 THAILAND BIOPSY INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 218 THAILAND CONSUMABLES AND ACCESSORIES IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 219 THAILAND KITS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 220 THAILAND REAGENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 221 THAILAND LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 222 THAILAND BIOMARKERS TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 223 THAILAND IMAGING TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 224 THAILAND BIOPSY IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 225 THAILAND BLOOD TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 226 THAILAND LUNG CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 227 THAILAND LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 228 THAILAND LUNG CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 229 NEW ZEALAND LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 230 NEW ZEALAND INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 231 NEW ZEALAND PATHOLOGY-BASED INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 232 NEW ZEALAND IMAGING INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 233 NEW ZEALAND BIOPSY INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 234 NEW ZEALAND CONSUMABLES AND ACCESSORIES IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 235 NEW ZEALAND KITS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 236 NEW ZEALAND REAGENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 237 NEW ZEALAND LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 238 NEW ZEALAND BIOMARKERS TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 239 NEW ZEALAND IMAGING TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 240 NEW ZEALAND BIOPSY IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 241 NEW ZEALAND BLOOD TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 242 NEW ZEALAND LUNG CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 243 NEW ZEALAND LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 244 NEW ZEALAND LUNG CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 245 TAIWAN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 246 TAIWAN INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 247 TAIWAN PATHOLOGY-BASED INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 248 TAIWAN IMAGING INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 249 TAIWAN BIOPSY INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 250 TAIWAN CONSUMABLES AND ACCESSORIES IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 251 TAIWAN KITS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 252 TAIWAN REAGENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 253 TAIWAN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 254 TAIWAN BIOMARKERS TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 255 TAIWAN IMAGING TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 256 TAIWAN BIOPSY IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 257 TAIWAN BLOOD TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 258 TAIWAN LUNG CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 259 TAIWAN LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 260 TAIWAN LUNG CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 261 REST OF ASIA-PACIFIC LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
List of Figure
FIGURE 1 ASIA PACIFIC LUNG CANCER DIAGNOSTICS MARKET: SEGMENTATION
FIGURE 2 ASIA PACIFIC LUNG CANCER DIAGNOSTICS MARKET: DATA TRIANGULATION
FIGURE 3 ASIA PACIFIC LUNGS CANCER DIAGNOSTICS MARKET: DROC ANALYSIS
FIGURE 4 ASIA PACIFIC LUNG CANCER DIAGNOSTICS MARKET: ASIA PACIFIC VS REGIONAL MARKET ANALYSIS
FIGURE 5 ASIA PACIFIC LUNG CANCER DIAGNOSTIC MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 ASIA PACIFIC LUNG CANCER DIAGNOSTICS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 ASIA PACIFIC LUNG CANCER DIAGNOSTICS MARKET: DBMR MARKET POSITION GRID
FIGURE 8 ASIA PACIFIC LUNG CANCER DIAGNOSTICS MARKET: MARKET END USER COVERAGE GRID
FIGURE 9 ASIA PACIFIC LUNG CANCER DIAGNOSTICS MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 ASIA PACIFIC LUNG CANCER DIAGNOSTICS MARKET: SEGMENTATION
FIGURE 11 THE INCREASE IN THE AWARENESS ABOUT LUNG CANCER IS EXPECTED TO DRIVE THE ASIA PACIFIC LUNG CANCER DIAGNOSTICS MARKET IN THE FORECAST PERIOD
FIGURE 12 INSTRUMENTS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA PACIFIC LUNG CANCER DIAGNOSTICS MARKET IN 2023 & 2030
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE ASIA PACIFIC LUNG CANCER DIAGNOSTICS MARKET
FIGURE 14 THE ASIA PACIFIC MORTALITY RATE DUE TO CANCER
FIGURE 15 THE DATA GIVEN BELOW SHOWS THE INCREASING ASIA PACIFIC CANCER RATE IN 2020
FIGURE 16 BARRIERS TO EARLY CANCER DIAGNOSIS AND TREATMENT
FIGURE 17 ASIA PACIFIC LUNG CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, 2022
FIGURE 18 ASIA PACIFIC LUNG CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, 2023-2030 (USD MILLION)
FIGURE 19 ASIA PACIFIC LUNG CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, CAGR (2023-2030)
FIGURE 20 ASIA PACIFIC LUNG CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, LIFELINE CURVE
FIGURE 21 ASIA PACIFIC LUNG CANCER DIAGNOSTICS MARKET: BY TEST TYPE, 2022
FIGURE 22 ASIA PACIFIC LUNG CANCER DIAGNOSTICS MARKET: BY TEST TYPE, 2023-2030 (USD MILLION)
FIGURE 23 ASIA PACIFIC LUNG CANCER DIAGNOSTICS MARKET: BY TEST TYPE, CAGR (2023-2030)
FIGURE 24 ASIA PACIFIC LUNG CANCER DIAGNOSTICS MARKET: BY TEST TYPE, LIFELINE CURVE
FIGURE 25 ASIA PACIFIC LUNG CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, 2022
FIGURE 26 ASIA PACIFIC LUNG CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, 2023-2030 (USD MILLION)
FIGURE 27 ASIA PACIFIC LUNG CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, CAGR (2023-2030)
FIGURE 28 ASIA PACIFIC LUNG CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, LIFELINE CURVE
FIGURE 29 ASIA PACIFIC LUNG CANCER DIAGNOSTICS MARKET: BY END USER, 2022
FIGURE 30 ASIA PACIFIC LUNG CANCER DIAGNOSTICS MARKET: BY END USER, 2023-2030 (USD MILLION)
FIGURE 31 ASIA PACIFIC LUNG CANCER DIAGNOSTICS MARKET: BY END USER, CAGR (2023-2030)
FIGURE 32 ASIA PACIFIC LUNG CANCER DIAGNOSTICS MARKET: BY END USER, LIFELINE CURVE
FIGURE 33 ASIA PACIFIC LUNG CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2022
FIGURE 34 ASIA PACIFIC LUNG CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)
FIGURE 35 ASIA PACIFIC LUNG CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)
FIGURE 36 ASIA PACIFIC LUNG CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 37 ASIA-PACIFIC LUNG CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022)
FIGURE 38 ASIA-PACIFIC LUNG CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022)
FIGURE 39 ASIA-PACIFIC LUNG CANCER DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030)
FIGURE 40 ASIA-PACIFIC LUNG CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030)
FIGURE 41 ASIA-PACIFIC LUNG CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE (2023-2030)
FIGURE 42 ASIA PACIFIC LUNG CANCER DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%)
Research Methodology
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
Customization Available
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
